China NMPA Fee Catalogue for Drugs & Medical Devices

Understanding China NMPA registration fees is essential for pharmaceutical and medical device companies planning market entry into China. Administrative licensing costs imposed by the National Medical Products Administration (NMPA) represent an important component of regulatory expenditure, although for many products they account for only a fraction of total market-entry costs. Clinical development, testing requirements, manufacturing compliance activities, and lifecycle management decisions often have a significantly greater impact on the overall investment required for China market access.  

Beyond the official filing charges themselves, companies must also consider technical review costs, clinical trial expenses, product specification strategies, and long-term post-approval maintenance obligations. 

Continue below for a full breakdown of China NMPA registration fees or contact Cisema for support with pharmaceutical and medical device market entry in China.

Note on USD figures: All USD equivalents are approximate and provided for orientation only. Actual USD values will vary depending on prevailing exchange rates. RMB fee figures should be considered authoritative.

Imported Drug Registration Fees in China

Imported pharmaceutical products face some of the highest administrative fees under the NMPA framework. Costs vary depending on whether the application involves a new drug, a generic product, or a post-approval change requiring technical review.

New Drug Applications

For imported innovative or new pharmaceutical products, companies typically encounter two major regulatory filing stages before commercialization: 

• Clinical Trial Application — RMB 376,000 (~USD 55,000)
• Marketing Authorization Application — RMB 593,900 (~USD 87,000)  

Generic Drug Applications

Imported generic drugs generally face lower registration costs than innovative products, although fees increase when additional clinical studies are required. 

• Marketing Authorization (without clinical trials) — RMB 367,600 (~USD 54,000)  
• Marketing Authorization (with clinical trials) — RMB 502,000 (~USD 74,000)  

Post-Approval Drug Registration Fees Companies Often Overlook 

After obtaining approval, pharmaceutical companies may still incur substantial administrative costs for lifecycle maintenance activities. 

• Supplementary Application requiring technical review — RMB 283,600 (~USD 41,000) 

Domestic Drug Registration Fees in China 

Domestic registration fees are generally lower than imported product fees, which can influence localization strategies for multinational companies manufacturing in China through subsidiaries or contract manufacturers. 

Domestic New Drug Filing Fees 

• Clinical Trial Application — RMB 192,000 (~USD 28,000)  
• Marketing Authorization Application — RMB 432,000 (~USD 63,000)  

Generic Drug Applications 

• Marketing Authorization (without clinical trials) — RMB 183,600 (~USD 27,000)  

Additional Regulatory Filings 

Lifecycle maintenance filings remain necessary for domestic products as well. 

• Supplementary Application requiring technical review — RMB 99,600 (~USD 14,000)  

Imported Medical Device Registration Fees in China 

Medical device registration costs in China vary according to device classification and registration activity. Higher-risk devices typically involve greater administrative fees because regulators conduct more extensive technical reviews and safety assessments. 

Class III Medical Device Registration Fees 

Class III devices represent the highest-risk category and therefore face the highest registration costs.

Class II Medical Device Registration Fees 

• First Registration — RMB 210,900 (~USD 29,000)  
• Change Registration — RMB 42,000 (~USD 5,800)  

Domestic Class III Medical Devices 

Medical Device Clinical Trial Application Fees

Clinical trial fees apply regardless of whether the device is imported or domestically manufactured. High-risk medical device clinical trial application — RMB 43,200 (~USD 6,000).

Key Cost Drivers in China NMPA Registration

Administrative filing fees alone rarely reflect the full cost of China registration. Several additional factors can significantly increase or reduce overall registration expenses.

Additional Product Specifications Can Increase Registration Costs

Under the current fee catalogue, additional product specifications may increase registration fees for certain application categories.

This may affect companies registering:

• Multiple package sizes
• Different dosage strengths
• Device size variations
• Product configuration options

Careful planning of product specifications during development and registration strategy can help companies avoid unnecessary regulatory costs with simplifying dossier preparation and lifecycle management.

The Long-Term Cost of Post-Approval Changes

Post-approval changes remain one of the most underestimated long-term regulatory expenses for imported products.

For imported drugs, supplementary applications requiring technical review cost RMB 283,600 (~USD 41,000).

Companies that frequently modify formulations, manufacturing processes, labeling, or specifications may therefore face recurring administrative expenses throughout the product lifecycle.

5 Strategies to Reduce China NMPA Registration Costs

Companies that manage China registration costs effectively usually do so long before submission begins. Early regulatory planning can significantly reduce avoidable expenses, delays, and repeat filings.

The strategies below can help foreign manufacturers reduce total regulatory spend while improving approval timelines.

1. Consolidate Product Specifications Early

One of the most effective ways to control costs is to minimize unnecessary product specifications during initial registration.

If specifications are not carefully planned, companies may face incomplete or inconsistent dossiers, which often lead to supplementary review requests, delayed approvals, and costly corrective filings. Careful, comprehensive documentation preparation reduces these risks and streamlines the registration process.

2. Assess Clinical Trial Requirements Early

Clinical trial obligations can significantly affect both timelines and budgets. Conducting an early gap assessment helps companies determine whether local studies are necessary, allowing them to plan more efficiently and avoid unexpected delays or expenses.

Early clinical trial planning is often one of the most important factors in a successful China registration strategy. Our article, Accelerating NMPA Approval: Building the Right China Medical Device Clinical Trial Strategy from Day 1, explores how companies can prepare more effectively for NMPA review.

3. Minimize Post-Approval Modifications

Frequent product changes create recurring supplementary application expenses. By maintaining stable product configurations, companies can lower lifecycle compliance costs and reduce the administrative burden throughout the product’s life.

4. Evaluate Innovation Incentives Before Filing

Companies developing potentially innovative products should assess eligibility for NMPA innovation designation programs and related fee incentives early in development. Early assessment can help maximize potential cost savings and support more effective regulatory planning.

5. Work With Experienced China Regulatory Specialists

Engaging experienced regulatory specialists, such as Cisema, can help companies identify potential regulatory challenges early, develop more efficient registration strategies, and avoid common compliance pitfalls that may lead to delays, rework, or additional expenses.

Final Thoughts: Strategic Planning Is Essential for NMPA Cost Control

While NMPA administrative fees are often used as a proxy for market-entry costs, they rarely reflect the overall investment required for China registration. Regulatory strategy, clinical requirements, testing obligations, manufacturing readiness, and lifecycle management decisions typically have a far greater impact on total program costs than the administrative fees themselves.

Companies that approach China registration strategically, with disciplined specification planning, early regulatory assessment, and strong lifecycle management, are better positioned to control costs and accelerate market entry.

From initial registration strategy through post-approval compliance, Cisema helps pharmaceutical and medical device companies navigate China’s regulatory framework more efficiently, reduce avoidable costs, and bring products to market faster.

For tailored guidance on China NMPA registration for pharmaceuticals and medical devices, contact Cisema today.

Further Information

Explore Cisema’s services for: 

• Pharmaceutical Consulting 
• Medical device registration services in China 

Learn more in our article, Medical Devices in China: A Regulatory Glossary for NMPA Compliance, for a practical overview of the terminology and compliance requirements relevant to medical device market entry in China.

Read Accelerating NMPA Approval: Building the Right China Medical Device Clinical Trial Strategy from Day 1 to learn how early planning can help support a smoother path to market.